Heidi P. Fransen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Heidi P. Fransen has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Natasja J. H. Raijmakers
Department of Research & Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands
4 shared publications - Hanneke Wilma Marlies van Laarhoven
Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, the Netherlands
2 shared publications - Lonneke V. van de Poll-Franse
Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute, 1066 CX Amsterdam, The Netherlands
2 shared publications - Agnes Jager
Department of Medical Oncology, Erasmus University MC Cancer Institute, Rotterdam, The Netherlands
1 shared publication - Anna Katrien Leontien Reyners
Department of Medical Oncology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
1 shared publication Annemieke van der Padt-Pruijsten
Department of Research and Development The Netherlands Comprehensive Cancer Organisation Utrecht The Netherlands
1 shared publication
Latest Publications
- 6 October 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-9
Trends in incidence and prevalence of patients living long-term with de novo metastatic incurable cancer: a retrospective cohort study
Background Therapeutic advances have improved the survival of incurable cancer patients, creating a growing population living long-term with incurable cancer. However, little is known about their epidemiological characteristics. We aimed to examine trends in annual incidence and prevalence among patients living long-term with de novo metastatic incurable cancer in the Netherlands and to describe additional relevant sociodemographic and clinical characteristics among patients diagnosed in recent years. Methods A population-based, retrospective cohort study using data from the Netherlands Cancer Registry was performed. Adults (≥18 years) diagnosed with de novo metastatic solid tumors in 2000–2021 who survived ≥2 years after their diagnosis were included. Annual incidence, prevalence, key demographic, and tumor characteristics were calculated. Results Annual incident cases of patients living long-term with de novo metastatic incurable cancer increased from 1298 (2000) to 5398 (2021), representing 12.0–22.6% of incurable cancer diagnoses. In February 2024, at least 18,466 patients in the Netherlands were living long-term with de novo metastatic incurable cancer (1 per 1000 inhabitants). Mean age was 64 years (SD 12), 59.4% were male, and 55.8% (n = 10,310) were alive 2- < 5 years after diagnosis, 31.0% (n = 5721) 5- < 10 years, and 13.2% (n = 2435) ≥ 10 years. The most common tumor types were prostate (35.6%), lung (20.2%), breast (14.4%), and colorectal cancer (6.3%). Conclusion Substantial increases in the incidence and prevalence were identified, reflecting a shift toward prolonged survival within the incurable cancer population. Greater awareness and research are needed to inform care for this emerging group.
- 6 October 2026
- Published by Springer Nature in British Journal of Cancer
- p. 1-9
Trends in incidence and prevalence of patients living long-term with de novo metastatic incurable cancer: a retrospective cohort study
Background Therapeutic advances have improved the survival of incurable cancer patients, creating a growing population living long-term with incurable cancer. However, little is known about their epidemiological characteristics. We aimed to examine trends in annual incidence and prevalence among patients living long-term with de novo metastatic incurable cancer in the Netherlands and to describe additional relevant sociodemographic and clinical characteristics among patients diagnosed in recent years. Methods A population-based, retrospective cohort study using data from the Netherlands Cancer Registry was performed. Adults (≥18 years) diagnosed with de novo metastatic solid tumors in 2000–2021 who survived ≥2 years after their diagnosis were included. Annual incidence, prevalence, key demographic, and tumor characteristics were calculated. Results Annual incident cases of patients living long-term with de novo metastatic incurable cancer increased from 1298 (2000) to 5398 (2021), representing 12.0–22.6% of incurable cancer diagnoses. In February 2024, at least 18,466 patients in the Netherlands were living long-term with de novo metastatic incurable cancer (1 per 1000 inhabitants). Mean age was 64 years (SD 12), 59.4% were male, and 55.8% (n = 10,310) were alive 2- < 5 years after diagnosis, 31.0% (n = 5721) 5- < 10 years, and 13.2% (n = 2435) ≥ 10 years. The most common tumor types were prostate (35.6%), lung (20.2%), breast (14.4%), and colorectal cancer (6.3%). Conclusion Substantial increases in the incidence and prevalence were identified, reflecting a shift toward prolonged survival within the incurable cancer population. Greater awareness and research are needed to inform care for this emerging group.
- Open Access
Sexual health at the end of life in patients with advanced cancer and their partners. Results of a Dutch prospective longitudinal study (eQuiPe)
Background: Sexual health can be negatively affected by cancer. There is a paucity of literature exploring changes in sexual health during the end of life. Aim: To assess changes in sexual health in patients with advanced cancer and their partners at the end of life, and to identify the associated factors. Design: A prospective longitudinal study of patients with advanced cancer and their partners on the quality of care and quality of life (QoL) (eQuiPe). Patients and partners completed 3-monthly questionnaires. Sexual health (desire, activity, satisfaction and enjoyment) was measured using the EORTC QLQ-SH22. Setting/participants: Patients aged ≥18 years and diagnosed with advanced cancer were recruited in one of the forty participating Dutch hospitals. Relatives were recruited through patients, and for this study only couples (patient-partner) were included (n=352). Results: Towards death, patients remained relatively stable in sexual activity (range 15-19), satisfaction (range 40-45), and enjoyment (range 30-44). Similar results were found for partners. In patients, sexual desire significantly decreased towards the end of life (β 0.4, 95%CI 0.1-0.7). Moreover, greater decline in physical functioning was associated with poorer outcomes in most aspects of sexual health. Sexual desire, activity and satisfaction were individually associated with QoL in patients. Conclusions: Sexual health remains relatively stable at the end of life in patients with advanced cancer and their partner. Patients with worse physical functioning report worse sexual health and sexual desire, activity and satisfaction are individually associated with better QoL. Therefore, addressing sexual health in palliative care is essential.
Open AccessSexual health at the end of life in patients with advanced cancer and their partners. Results of a Dutch prospective longitudinal study (eQuiPe)
Background: Sexual health can be negatively affected by cancer. There is a paucity of literature exploring changes in sexual health during the end of life. Aim: To assess changes in sexual health in patients with advanced cancer and their partners at the end of life, and to identify the associated factors. Design: A prospective longitudinal study of patients with advanced cancer and their partners on the quality of care and quality of life (QoL) (eQuiPe). Patients and partners completed 3-monthly questionnaires. Sexual health (desire, activity, satisfaction and enjoyment) was measured using the EORTC QLQ-SH22. Setting/participants: Patients aged ≥18 years and diagnosed with advanced cancer were recruited in one of the forty participating Dutch hospitals. Relatives were recruited through patients, and for this study only couples (patient-partner) were included (n=352). Results: Towards death, patients remained relatively stable in sexual activity (range 15-19), satisfaction (range 40-45), and enjoyment (range 30-44). Similar results were found for partners. In patients, sexual desire significantly decreased towards the end of life (β 0.4, 95%CI 0.1-0.7). Moreover, greater decline in physical functioning was associated with poorer outcomes in most aspects of sexual health. Sexual desire, activity and satisfaction were individually associated with QoL in patients. Conclusions: Sexual health remains relatively stable at the end of life in patients with advanced cancer and their partner. Patients with worse physical functioning report worse sexual health and sexual desire, activity and satisfaction are individually associated with better QoL. Therefore, addressing sexual health in palliative care is essential.
- 20 October 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34, S886-S887
1594P End-of-life hospital cancer care in the COVID-19 era: A retrospective population-based study in the Netherlands
- 20 October 2023
- Published by Elsevier in Annals of Oncology
- Vol. 34, S886-S887
1594P End-of-life hospital cancer care in the COVID-19 era: A retrospective population-based study in the Netherlands
- 27 February 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 165, 125-135
Quality of life and quality of care as experienced by patients with advanced cancer and their relatives: A multicentre observational cohort study (eQuiPe)
- 27 February 2022
- Published by Elsevier in European Journal of Cancer
- Vol. 165, 125-135
Quality of life and quality of care as experienced by patients with advanced cancer and their relatives: A multicentre observational cohort study (eQuiPe)